Strategies to tackle RAS-mutated metastatic colorectal cancer

The RAS oncogene is among the most commonly mutated in cancer. RAS mutations are identified in about half of patients diagnosed with metastatic colorectal cancer (mCRC), conferring poor prognosis and lack of response to anti-epidermal growth factor receptor (EGFR) antibodies. In the last decades, se...

Descripción completa

Detalles Bibliográficos
Autores principales: Patelli, G., Tosi, F., Amatu, A., Mauri, G., Curaba, A., Patanè, D.A., Pani, A., Scaglione, F., Siena, S., Sartore-Bianchi, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167159/
https://www.ncbi.nlm.nih.gov/pubmed/34044286
http://dx.doi.org/10.1016/j.esmoop.2021.100156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8167159/
https://www.ncbi.nlm.nih.gov/pubmed/34044286
http://dx.doi.org/10.1016/j.esmoop.2021.100156

Ejemplares similares